15,694 reports of this reaction
3.3% of all AMLODIPINE reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for AMLODIPINE, manufactured by Azurity Pharmaceuticals, Inc.. There are 15,694 FDA adverse event reports linking AMLODIPINE to FATIGUE. This represents approximately 3.3% of all 472,892 adverse event reports for this drug.
Patients taking AMLODIPINE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among AMLODIPINE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for AMLODIPINE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 15,694 FDA reports for AMLODIPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.3% of all adverse event reports for AMLODIPINE, making it one of the most commonly reported side effect.
If you experience fatigue while taking AMLODIPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.